Automated Quantitative Cytology Imaging Analysis System in Cervical Cancer Screening in Shanxi Province, China

Purpose: In China the number of pathologists is far from being enough to meet the demands of ongoing population based cervical cancer screening programs. This article aims to present our experience with automated quantitative cytology imaging platform, a reading system with an artificial intelligence that we currently use routinely for cervical cancer screening in Shanxi province.Methods: From 2012-2016 a total of 40 178 women were screened. Women were divided into three groups and each group had two subgroups. Smear and liquid based technique were compared using manual and automated platform.Results: Detection rates of CIN2 + and positive rates of CIN2 were higher in all three groups when automated quantitative cytology platform was used compared with groups where reading was done by the pathologist using conventional microscope. Operator’s costs associated with automated quantitative cytology platform vs. conventional reading using light microscope were compared too. The overall costs of operations based on automated platform were proven to be lower.Conclusion: The use of automated platform and artificial intelligence as a means to overcome the lack of cytotechnologists and pathologists and to implement proper quality control in the large scale population based cervical cancer screening seems very promising.

Dr. Bibbo's Presidential Address on Automation in Cytology: Were Her Predictions Right, Wrong, or Somewhere in the Middle?

In 1983, Dr. Marluce Bibbo gave the Presidential Address at the Annual Meeting of the American Society of Cytology in Denver, CO, USA. The lecture was entitled “Analytic and Quantitative Cytology,” a field in which Dr. Bibbo was intimately involved. In the presentation, she included a summary of 30 years of work already accomplished, the present state of the art, and musings about issues encountered, potential resolutions, progress that needed to be made, and her perception of how the field needed to evolve in order to become ultimately successful as a clinical service. This commentary looks back 34 years, with observations about Dr. Bibbo's predictions and how the field of cytology automation did actually evolve in the decades following her address. New challenges are identified and possible paths forward are discussed.